reslizumab

Absorption: IV administration results in complete bioavailability.

Distribution: Minimal distribution to tissues.

Metabolism/Excretion: Degraded by proteolytic enzymes located throughout the body.

Half-Life: 24 days.

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTE	ONSET	PEAK	DURATION
IV	unknown	End of infusion	unknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
Acute bronchospasm.

Use Cautiously in:

OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

MS: ↑creatine kinase, muscle spasms, myalgia, pain

Misc: ANAPHYLAXIS, MALIGNANCY

Interactions ⬆ ⬇

Drug-drug:

None reported.

Route/Dosage ⬆ ⬇

IV (Adults ): 3 mg/kg every 4 wk.

Availability ⬆ ⬇

Solution for injection: 10 mg/mL

Assessment ⬆ ⬇

Assess respiratory status (rate, breath sounds, degree of dyspnea, pulse) periodically during therapy.
Monitor for signs and symptoms of anaphylaxis (dyspnea, ↓ oxygen saturation, wheezing, vomiting, urticaria) during and following infusion. Anaphylaxis may occur during or within 20 min of infusion and as soon as second dose of reslizumab. If severe systemic reactions occur, stop infusion immediately and provide supportive medical treatment. Discontinue reslizumab permanently if signs and symptoms of anaphylaxis occur.
Assess for and treat parasitic infections prior to therapy. If infected during therapy and unresponsive to anti-helminth treatment, discontinue reslizumab until infection resolves.

Lab Test Considerations:

May cause ↑ creatine kinase.

Implementation ⬆ ⬇

Only administer by a health care professional able to manage anaphylaxis. Do not use to treat acute asthma symptoms or exacerbations, acute bronchospasm, or status asthmaticus.
- Do not abruptly discontinue systemic or inhaled corticosteroids following administration of reslizumab. ↓ in corticosteroid dose should be gradual and under supervision of health care professional. ↓ in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by corticosteroid therapy.

IV Administration:

Intermittent Infusion: Allow solution to reach room temperature. Withdraw volume from reslizumab vial and add to 50 mL 0.9% NaCl in a polyvinyl or polyolefin bag. Invert gently to mix; do not shake. Solution is clear to slightly hazy/opalescent, colorless to slightly yellow; may contain translucent to white, amorphous, proteinaceous particles. Do not administer solutions that are discolored or cloudy. Store in refrigerator or at room temperature, protected from light, for up to 16 hrs.
Rate: Infuse over 20–50 min via an in-line, low protein-binding 0.2 micron filter. Do not administer as IV push or bolus. Flush IV with 0.9% NaCl upon completion of infusion.
Y-Site Incompatibility: Do not administer in same IV line as other agents.

Patient/Family Teaching ⬆ ⬇

Inform patient of risk and signs and symptoms of anaphylaxis. Instruct patient to notify health care professional immediately if signs and symptoms of anaphylaxis occur.
Inform patient that reslizumab does not treat acute asthma symptoms. Advise patient to notify health care professional if asthma remains uncontrolled or worsens after reslizumab therapy.
Counsel patient about the increased risk of malignancies in patients taking reslizumab.
Caution patient not to ↓ corticosteroid dose unless instructed by health care professional.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes ⬆ ⬇

Reduction in asthma exacerbations.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

59310- Teva Respiratory, LLC
- 59310-610- CINQAIR
  - 59310-610-31- 1 VIAL, SINGLE-USE in 1 CARTON (59310-610-31) > 10 mL in 1 VIAL, SINGLE-USE

59310- Teva Respiratory, LLC
- 59310-610- CINQAIR
  - 59310-610-33- 1 VIAL, SINGLE-USE in 1 CARTON (59310-610-33) > 10 mL in 1 VIAL, SINGLE-USE

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇